本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 贵州百灵企业集团制药股份有限公司（以下简称"公司"）2022 年年度报告全文及摘要已于 2023 年 4 月 29 日刊登于中国证监会指定 信息披露网站巨潮资讯网（www.cninfo.com.cn）。为加强与投资者 的交流互动，便于投资者进一步了解公司 2022 年度经营情况及其他 关切问题，公司定于 2023 年 5 月 15 日（星期一）下午 15:00 - 17:00 采用网络远程的方式举行 2022 年度业绩说明会。本次年度业绩说明 会通过深圳证券交易所提供的"互动易"平台举行，投资者可登录"互 动易"平台（http://irm.cninfo.com.cn）,进入"云访谈"栏目参 与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：公司董事长姜伟先生，公司 总经理、董事、董事会秘书牛民先生，财务总监李红星先生，监事会 主席、研发总监夏文先生，独立董事胡坚先生。 证券代码：002424 证券简称：贵州百灵 公告编号：2023-030 贵州百灵企业集团制药股份有限公司 关于举行2022年度网上业绩说明会 ...

证券代码：贵州百灵 证券简称：002424 编号：2023-001 ☑特定对象调研 □分析师会议 投资者关系活动 类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及 赵垒 兴业银行股份有限公司资产管理部 人员姓名 林恒 上海汐泰投资管理有限公司 牛悦 新华养老保险股份有限公司 何壟 磐石投资 曹姗姗 上海盘京投资管理中心（有限合伙） 陈健 四海恒通控股集团 周少博 泰达宏利基金管理有限公司 廖仕超 深圳市前海进化论资产管理有限公司 徐宏 上海东方证券资产管理有限公司 陈红新 个人 景顺座机 景顺 颜孙挺 江阴米利都私募基金 李泽昱 汇添富基金管理股份有限公司 林恺伟 北京聚圆汇金资产管理有限公司 张山林 天演资产 吴瑶 上海趣时资产管理 王聪 亚太财产保险有限公司 李进鹏 磐石投资 张倬颖 淳厚基金管理有限公司 贵州百灵企业集团制药股份有限公司投资者关系活动记录表 王益 宁波信本资产管理有限公司 张国玺 个人 杨柳 天演资产 戚建炆 磐石投资 赵娜 财信证券股份有限公司 周小萃（投资经理） 上海汐泰投资管理有限公司 赵琛 广发证券 周登泉 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 1,091,626,153.16, representing a 47.77% increase compared to CNY 738,716,135.73 in the same period last year[6] - Net profit attributable to shareholders was CNY 92,306,394.78, up 41.81% from CNY 65,091,265.16 year-on-year[6] - The net profit after deducting non-recurring gains and losses was CNY 88,450,072.54, reflecting a 39.52% increase from CNY 63,395,941.66 in the previous year[6] - Basic earnings per share increased to CNY 0.07, a 40.00% rise from CNY 0.05 in the previous year[6] - The total net profit for the first quarter was ¥91,853,787.63, an increase from ¥65,443,727.95 in the previous year, representing a growth of approximately 40.5%[26] - The total profit for the quarter was ¥125,645,269.48, an increase from ¥76,902,148.00, representing a growth of approximately 63.5%[26] - The operating profit for the quarter was ¥125,845,080.06, compared to ¥76,426,407.88 in the same period last year, indicating a year-over-year increase of about 64.6%[26] - The total comprehensive income attributable to the parent company was ¥92,306,394.78, up from ¥65,091,265.16, reflecting a growth of approximately 41.8%[26] Cash Flow and Liquidity - The company's cash flow from operating activities showed a net outflow of CNY 57,871,366.46, worsening by 91.89% compared to a net outflow of CNY 30,159,281.86 in the same period last year[17] - The cash inflow from operating activities was ¥1,261,822,831.44, compared to ¥1,207,463,600.90 in the previous period, showing an increase of about 4.5%[46] - The net cash flow from operating activities was -¥57,871,366.46, worsening from -¥30,159,281.86 year-over-year[46] - The cash and cash equivalents at the end of the quarter stood at ¥471,054,001.52, down from ¥243,346,914.42 at the end of the previous year[28] - The company's cash and cash equivalents at the end of the reporting period were CNY 504,546,972.09, down from CNY 605,022,761.98 at the beginning of the year, reflecting a decrease of approximately 16.6%[23] - The company reported a net decrease in cash and cash equivalents of ¥55,701,701.26 for the quarter, an improvement from a decrease of ¥76,096,096.33 in the previous year[28] Assets and Liabilities - The total assets at the end of the reporting period were CNY 7,085,935,939.92, a 2.78% increase from CNY 6,894,398,806.75 at the end of the previous year[6] - The total assets increased to ¥7,085,935,939.92, up from ¥6,894,398,806.75, representing a growth of approximately 2.8%[41] - The total liabilities rose to ¥3,097,183,507.47, an increase of approximately 6.9% from ¥2,897,493,904.00[41] - The total operating costs for the first quarter of 2023 were CNY 939,198,900.08, up from CNY 631,703,412.81, indicating an increase of about 48.5%[25] - Accounts receivable increased to CNY 1,845,275,289.62 from CNY 1,534,084,461.23, marking a rise of about 20.3%[23] - The company's inventory at the end of the reporting period was CNY 833,474,079.50, an increase from CNY 804,826,437.54, representing a growth of approximately 3.6%[23] - The total liabilities and equity of the company reached CNY 7,085,935,939.92, compared to CNY 6,894,398,806.75 at the beginning of the year, indicating an increase of about 2.8%[25] Equity and Investments - The total equity attributable to shareholders decreased slightly by 0.19% to CNY 3,986,935,775.71 from CNY 3,994,635,638.86 at the end of the previous year[6] - The total equity attributable to shareholders of the parent company was CNY 3,986,935,775.71, slightly down from CNY 3,994,635,638.86, indicating a decrease of about 0.2%[25] - The company's retained earnings rose to CNY 2,266,277,434.14 from CNY 2,173,971,039.36, reflecting an increase of about 4.2%[25] - The company reported a net investment loss of CNY 4,347,137.40, an improvement from a loss of CNY 15,761,429.78 in the previous period[25] - The company received cash from borrowings amounting to ¥476,700,000.00, compared to ¥332,800,000.00 in the previous year, showing a significant increase of 43.2%[28] Research and Development - The company's R&D expenses surged by 300.43% to CNY 16,358,969.36, compared to CNY 4,085,372.30 in the same period last year, indicating increased investment in innovation[16] Income and Taxation - The income tax expense for the quarter was ¥33,791,481.85, compared to ¥11,458,420.05 in the previous year, indicating a rise of about 194.5%[26] - The company reported a significant increase in other income, which rose by 269.89% to CNY 5,344,041.61, primarily due to government subsidies received[16]

Financial Performance - The company's total revenue for 2022 was approximately ¥3.54 billion, representing a 13.79% increase compared to 2021[12]. - The net profit attributable to shareholders for 2022 was approximately ¥138.20 million, an increase of 16.64% from the previous year[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥83.51 million, reflecting a 5.49% increase compared to 2021[12]. - The net cash flow from operating activities for 2022 was approximately ¥502.15 million, a significant increase of 54.55% from the previous year[12]. - The company's total assets at the end of 2022 were approximately ¥6.89 billion, marking a 6.50% increase from the end of 2021[12]. - The net assets attributable to shareholders at the end of 2022 were approximately ¥3.99 billion, a 3.09% increase compared to the end of 2021[12]. - The company reported a basic earnings per share of ¥0.10 for 2022, a 25.00% increase from the previous year[12]. - The company reported a gross margin of 60%, maintaining a stable margin compared to the previous year[48]. - The company reported a net fundraising amount of RMB 1,387,904,553.00 from the issuance of 37 million shares at an issue price of RMB 40.00 per share[120]. - The company reported a total asset adjustment of RMB 6,473,829,630.09 after correcting prior year errors[180]. Market and Product Strategy - The company continues to focus on its core products, including proprietary medicines and traditional Chinese medicine, with no significant changes in its main business operations[16]. - The company is actively expanding its market presence in the integrated traditional Chinese medicine sector, particularly with its core product, Tang Ning Tong Luo[16]. - The company plans to enhance its product quality and innovation capabilities in response to the intensified competition and regulatory environment in the pharmaceutical industry[27]. - Guizhou Bailing plans to launch three new products in the next fiscal year, focusing on diabetes management and traditional Chinese medicine[48]. - The company is investing RMB 50 million in R&D for new technologies aimed at enhancing product efficacy and safety[48]. - The company aims to strengthen its leading position in the herbal medicine sector and enhance its core competitiveness in traditional Chinese medicine[64]. - The company is focusing on the integration of traditional Chinese medicine and modern healthcare, with a complete industrial chain covering planting, manufacturing, distribution, and healthcare services[65]. - The company is actively engaged in new drug research and development, with projects covering multiple therapeutic areas, which will enhance its product portfolio and competitiveness[88]. Industry Context - In 2022, the revenue of China's pharmaceutical manufacturing industry was 2,911.14 billion yuan, a year-on-year decrease of 1.6%[24]. - The total profit of the pharmaceutical manufacturing industry in 2022 was 428.87 billion yuan, down 31.8% year-on-year[24]. - The cumulative operating costs for the pharmaceutical manufacturing industry in 2022 reached 1,698.46 billion yuan, an increase of 7.8% year-on-year[24]. - The national centralized procurement of traditional Chinese medicine (TCM) began in September 2022, covering 30 provincial regions with the first batch involving 16 product categories[25]. - The "14th Five-Year" plan for TCM development emphasizes high-quality development and has set specific development goals and indicators[32]. - The aging population and increasing health awareness are expected to drive continuous growth in the pharmaceutical market, indicating a robust demand[28]. Corporate Governance and Compliance - The company has not reported any significant discrepancies in its financial statements according to different accounting standards[1][2]. - The company has implemented strict internal control measures to enhance operational efficiency and cost management, contributing to improved profitability[82]. - The company has committed to ensuring independent operations and avoiding any actions that could harm the interests of shareholders[1]. - The company has emphasized the importance of maintaining compliance with corporate governance regulations without significant discrepancies[128]. - The company received an unqualified audit opinion with emphasis of matter from Tianjian Accounting Firm[189]. Social Responsibility and Sustainability - The management emphasized a commitment to sustainability and social responsibility initiatives, allocating RMB 10 million for community health programs[48]. - The company actively participates in social welfare and poverty alleviation initiatives, leveraging its advantages in the traditional Chinese medicine industry[9]. - The company has received national-level honors such as "Contract-abiding and Credit-worthy" for several years, reflecting its commitment to social responsibility[7]. - The company has achieved a daily wastewater treatment capacity of 5,000 tons with the completion of its second-phase wastewater treatment and reuse project[8]. - The company has transitioned to using gas boilers, shutting down two coal-fired boilers to reduce pollutant emissions[8]. Risk Management and Future Development - The company has identified potential risks and strategies for future development in its management discussion and analysis section[39]. - The company has undertaken measures to address cost risks as part of its future development strategy[126]. - The company is actively working to strengthen its marketing platform and improve sales management practices to achieve steady sales growth[125]. - The company has strengthened its marketing team while expanding into new markets, resulting in a stable price system for its products amid centralized drug procurement[82]. Miscellaneous - The company has made adjustments to its financial statements due to accounting errors from previous years, including unrecorded sales expenses totaling 65,042,230.13 yuan[34]. - The company has established a dynamic tracking system for large fund usage and guarantees, enhancing internal audit effectiveness[4]. - The company has established a new subsidiary, "Bailing (Nanjing) Health Management Co., Ltd." with a registered capital of RMB 5 million, in which the company holds an 80% stake[186]. - The company has a total approved external guarantee limit of RMB 59.20 million, with the actual balance also at RMB 59.20 million[130]. - The company has no reported penalties or rectification issues during the reporting period[162].

证券代码：002424 证券简称：贵州百灵 贵州百灵企业集团制药股份有限公司 投资者关系活动记录表 编号：2015-003 | --- | --- | --- | |----------------|--------------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | □ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 上海混沌道然资产管理有限公司：调研员 周宇 | | 人员姓名 | | | | 时间 | 2015 年 12 月 15 日 | 15：00 | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事、董事会秘书、总经理：牛民 | | | 员姓名 | 证券事务代表：陈智 | | | | 一、签署《承诺书》 | | | | 二、投资者与公司交流内容 | ...

证券代码：002424 证券简称：贵州百灵 贵州百灵企业集团制药股份有限公司 投资者关系活动记录表 编号：2015-002 | --- | --- | --- | --- | |----------------|--------------------------------|------------------------------------|------------------------------------------------------| | | | | | | 投资者关系活动 | □ 特定对象调研 | □ 分析师会议 | | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | | □ 新闻发布会 | □ 路演活动 | | | | 现场参观 | | | | | □ | | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | | 渤海证券部分有限公司：张雷（研究主管）王雯（医药行业 | | 人员姓名 | 分析师） | | | | | | | 国金证券股份有限公司：孙笑悦（医药行业分析师） | | 时间 | 2015 年 11 月 19 日 | 15：00 | | | 地 ...